Outlook's LYTENAVA Crosses The FDA Finish Line On Its Fourth Attempt - Now Comes The Commercial Test

India, July 24 -- The FDA has approved Outlook Therapeutics Inc.'s (OTLK) NS-5010/LYTENAVA for the treatment of neovascular age-related macular degeneration, commonly known as wet AMD.

Wet age-related macular degeneration (AMD) is an eye disease that affects the macula, the central part of the retina responsible for sharp, detailed vision. It occurs when abnormal blood vessels grow beneath the retina and leak fluid or blood, leading to swelling, damage to the macula, and progressive loss of central vision.

For comments and feedback contact: [e-mail]

Published by HT Digital Content Services with permission from RTT News....